Enhanced apoptosis and transforming growth factor-β1 expression in colorectal adenomas and carcinomas after sulindac therapy

Diseases of the Colon and Rectum

Volumn 44, Issue 7, 2001, Pages 1008-1015

  Masunaga, R ^a   Kohno, H ^a   Dhar, D K ^a   Kotoh, T ^a   Tabara, H ^a   Tachibana, M ^a   Kubota, H ^a   Nagasue, N ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Apoptosis; Colorectal neoplasm; Sulindac; TGF

Indexed keywords

SULINDAC; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER SURGERY; CLINICAL ARTICLE; COLON ADENOMA; COLORECTAL CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; PREOPERATIVE PERIOD; RECTUM ADENOMA; SCORING SYSTEM; TREATMENT OUTCOME; TUMOR BIOPSY;

EID: 0034959485     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02235490     Document Type: Conference Paper

References (35)

1. Aspirin use and reduced risk of fatal colon cancer
2. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells
3. The antiproliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: Alterations in tumor suppresser and cell cycle-regulatory proteins
4. Sulindac sulfide inhibits the proliferation of colon cancer cells: Diminished expression of the proliferation markers PCNA and Ki-67
5. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal antiinflammatory agent
6. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
7. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
8. Sulindac for polyposis of the colon
9. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
10. Effects of sulindac on sporadic colorectal adenomatous polyps
11. Clinical development plan: Sulindac
12. Eicosanoids and the gastrointestinal tract
13. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
14. Transformation of intestinal epithelial cells by chronic TGF-β1 treatment results in downregulation of type II TGF-β receptor and induction of cyclooxugenase-2
15. Coordinate regulation of cyclooxygenase-2 and TGF-β1 in replication errorpositive colon cancer and azoxymethane-induced rat colonic tumors
16. Physiological actions and clinical applications of transforming growth factor-β (TGFβ)
17. Phase I trial of sulindac plus 5-fiuorouracil and levamisole: Potential adjuvant therapy for colon carcinoma
18. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: Apoptotic index as a biomarker in colon cancer chemoprevention and promotion
19. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumor growth in rabbits
20. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
21. Induction of apoptosis by sulindac metabolites involves a p53 and bcl-2 independent mechanism and dose not require cell cycle arrest
22. A K-ras oncogene increases resistance to sulindac-induced apoptosis in rat enterocytes
23. Mechanisms underlying nonsteroidal antiinflammatory drugmediated apoptosis
24. Relationship of β-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in min mice
25. Stimulation of apoptosis by sulindac and piroxicam
26. Transforming growth factor β1 expression in human colorectal tumours: An independent prognostic marker in a subgroup of poor prognosis patients
27. Elevated serum levels of transforming growth factor-β1 in patients with colorectal carcinoma. Its association with tumor progression and its significant decrease after curative surgical resection
28. The type II transforming growth factor-β receptor as a tumor-suppresser gene
29. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability
30. Transforming growth factor β type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer
31. Transforming growth factor-β receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas
32. Mutations of the transforming growth factor-β type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability
33. Genetic instability and mutation of the TGF-βreceptor-II gene in ampullary carcinomas
34. Decreased levels of p26-Bcl-2, but not p30 phosphorylated Bcl-2, precede TGFβ1-induced apoptosis in colorectal adenoma cells
35. Higher frequency of smad4 gene mutation in human colorectal cancer with distant metastasis